SMBC Nikko Securities Starts Arrowhead Pharma (ARWR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $59.99 -1.22%
Rating Summary:
18 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 16 | New: 33
Rating Summary:
18 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 16 | New: 33
Join SI Premium – FREE
SMBC Nikko Securities analyst David Hoang initiates coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Outperform rating and a price target of $80.00.
For an analyst ratings summary and ratings history on Arrowhead Pharma click here. For more ratings news on Arrowhead Pharma click here.
Shares of Arrowhead Pharma closed at $33.58 yesterday.
You May Also Be Interested In
- Chardan Starts Zapata Computing (ZPTA) at Buy, 'A Pure-Play Quantum Software Opportunity'
- Berenberg Starts Ypsomed Holding AG (YPSN:SW) at Buy
- FDA grants Arrowhead's plozasiran entry into STAR pilot program
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
